¹Hopital Saint Vincent de Paul, Centre Universitaire de Dijon, Biocodex, Paris, France

Abstract

Background: Stiripentol (STP) is an antiepileptic drug which efficacy has been demonstrated in severe myoclonic epilepsy and strongly suggested in partial epilepsy as an add-on therapy. A pharmacokinetic (PK) study was performed in healthy volunteers as the linearity of STP PK remains controversial.

Methods: A randomised double blind cross-over study at 3 different single oral doses (500, 1000, 2000 mg as tablets) was performed in 12 subjects. Sixteen blood samples were collected in each subject. STP plasma concentrations were determined by HPLC. Data were analysed using a compartmental analysis.

Results: A two-compartment model with a zero order absorption (R0) and a significant lag-time fitted the data. The following parameters were calculated: Cmax (3.10.9, 7.11.9,13.23.6 mg/l), R0 (356194,742634, 871362 mg/h), Cl/F (5828, 3310, 258 l/h), AUC 0-inf (9.33.4, 33.110.9, 87.627.7 mg.h/l) and T1/2 (4.42.1, 10.13.3, 13.76.2 h) after the 500, 1000 and 2000 mg dosages respectively. Dose-normalized Log₁₀ (AUC) were found significantly different (p< 10^-10, ANOVA) between groups. However the half-life was not significantly different between the 1000 and the 2000 mg dosage.

Conclusion: A dose-dependent non-linear STP PK can be concluded, probably due to an increase in bioavailability, possibly a saturable first-pass effect. However stable concentrations are expected at steady-state as the elimination phase is linear (first order).